Equities

Allergy Therapeutics PLC

AGY:LSE

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.10
  • Today's Change-0.10 / -1.92%
  • Shares traded620.23k
  • 1 Year change183.33%
  • Beta1.9163
Data delayed at least 20 minutes, as of Nov 22 2024 15:39 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil, Oralvac and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

  • Revenue in GBP (TTM)55.20m
  • Net income in GBP-40.22m
  • Incorporated2004
  • Employees635.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Futura Medical PLC8.40m-3.75m100.75m12.00100.75m12.00
Scancell Holdings Plc0.00-5.86m134.79m61.00134.79m61.00
Faron Pharmaceuticals Oy0.00-26.30m148.85m34.00148.85m34.00
hVIVO PLC64.38m17.45m155.81m274.00155.81m274.00
4Basebio PLC596.00k-9.84m166.54m--166.54m--
Avacta Group Plc22.62m-25.89m171.73m154.00171.73m154.00
Bioventix PLC13.61m8.10m193.65m17.00193.65m17.00
Allergy Therapeutics plc55.20m-40.22m247.85m635.00247.85m635.00
Puretech Health PLC371.84k-65.52m389.83m90.00389.83m90.00
Oxford BioMedica plc97.28m-142.02m436.93m834.00436.93m834.00
Genus plc668.80m7.90m1.09bn3.44k1.09bn3.44k
Data as of Nov 22 2024. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

3.67%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Chase Bank, NA (Investment Management)as of 03 Sep 2024124.00m2.60%
West Yorkshire Pension Fundas of 03 Sep 202413.88m0.29%
Hargreaves Lansdown Asset Management Ltd.as of 03 Sep 202412.25m0.26%
IG Markets Ltd.as of 03 Sep 20249.79m0.21%
HSBC Global Asset Management (UK) Ltd.as of 03 Sep 20244.70m0.10%
Santander Asset Management SA SGIICas of 03 Sep 20243.13m0.07%
Hauck Aufh�user Lampe Privatbank AGas of 03 Sep 20242.35m0.05%
Raiffeisen Kapitalanlage-Gesellschaft mbHas of 03 Sep 20242.12m0.05%
iDealing.com Ltd.as of 03 Sep 20241.42m0.03%
Bank Julius B�r & Co. AGas of 03 Sep 20241.39m0.03%
More ▼
Data from 31 Mar 2024 - 05 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.